Although most of the KIF11 inhibitors tested in clinical trials had only limited efficacy, Arry-520 (also known as filanesib) has shown clinical efficacy in patients with multiple myeloma and has entered phase 3 clinical trials [4]. This evidence concerns the gene KIF11 and plasma cell myeloma.